Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2524902 | 1.00 | LMNA (0.44) | LMNACYP1A2CYP2C19TSHRTDP1 | |
| SCHEMBL1073150 | 1.00 | LMNA (0.44) | LMNACYP1A2CYP2C19TSHRTDP1 | |
| SCHEMBL294875 | 0.85 | LMNA (0.60) | LMNACYP1A2CYP2C19TSHRTDP1 | |
| SCHEMBL12212691 | 0.83 | LMNA (0.41) | LMNACYP1A2CYP2C19TSHRTDP1 | |
| SCHEMBL2520167 | 0.83 | LMNA (0.41) | LMNACYP1A2CYP2C19TSHRTDP1 | |
| SCHEMBL2167686 | 0.81 | LMNA (0.47) | LMNACYP1A2CYP2C19TSHRTDP1 | |
| SCHEMBL2167679 | 0.81 | LMNA (0.47) | LMNACYP1A2CYP2C19TSHRTDP1 | |
| SCHEMBL1073000 | 0.81 | LMNA (0.47) | LMNACYP1A2CYP2C19TSHRTDP1 | |
| SCHEMBL11239722 | 0.81 | LMNA (0.47) | LMNACYP1A2CYP2C19TSHRTDP1 | |
| SCHEMBL2167676 | 0.81 | LMNA (0.47) | LMNACYP1A2CYP2C19TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797953-B1 | PROCESS FOR PRODUCING OXYGENIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-7700799-B2 | Method for producing (2-formyl-1-alkenyl) cyclopropane compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20090137839-A1 | METHOD FOR PRODUCING (2-FORMYL-1-ALKENYL) CYCLOPROPANE COMPOUND | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7498459-B2 | Method for producing (1-alkenyl)cyclopropane compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20080064898-A1 | Method for Producing Oxygen-Containing Compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-13 | — | — | US | disclosed |
| US-7276622-B2 | Method for producing oxygen-containing compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-10-02 | — | — | US | disclosed |
| US-20070197818-A1 | Method for producing (1-alkenyl) cyclopropane compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-08-23 | — | — | US | disclosed |
| EP-1797953-A1 | PROCESS FOR PRODUCING OXYGENIC COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| EP-1728781-A1 | PROCESS FOR PRODUCTION OF (1-ALKENYL)CYCLOPROPANES | Sumitomo Chemical Company, Limited (JP) | 2006-12-06 | — | — | EP | disclosed |
| US-20060173221-A1 | Method for producing oxygen-containing compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-03 | — | — | US | disclosed |
| EP-1609777-A1 | METHOD FOR PRODUCING OXYGEN-CONTAINING COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2005-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137839-A1 | METHOD FOR PRODUCING (2-FORMYL-1-ALKENYL) CYCLOPROPANE COMPOUND | ACSL3, ACSL1, ARL1 | LMNA 2696/4885CYP1A2 53/4885CYP2C19 514/4885 |
| US-20080064898-A1 | Method for Producing Oxygen-Containing Compound | AOC2, AOX1, CAT | LMNA 3622/4885CYP1A2 256/4885CYP2C19 638/4885 |
| US-20060173221-A1 | Method for producing oxygen-containing compound | GPX4, DUOX2, SCO2 | LMNA 4036/4885CYP1A2 347/4885CYP2C19 563/4885 |
| US-20070197818-A1 | Method for producing (1-alkenyl) cyclopropane compound | ACSL3, ARL1, ACSL1 | LMNA 3763/4885CYP1A2 45/4885CYP2C19 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.